1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68EEB730EB337882485257D4700604B32
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-big-data-in-pharma-big-data-function-presence-and-valued-data-producers-across-medical-commercial-&-heor-segments?opendocument
18
19opendocument
2054.227.157.163
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services ╗ Market Research, Analytics and ForecastingAnalytics

Big Data in Pharma: Big Data Function Presence and Valued Data Producers across Medical, Commercial & HEOR Segments

ID: 5327


Features:

19 Info Graphics

13 Data Graphics

350+ Metrics

5 Narratives


Pages/Slides: 38


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Big Data in Pharma: Big Data Function Presence and Valued Data Producers across Medical, Commercial & HEOR Segments"


STUDY OVERVIEW

The 21st century has seen an explosion in the availability of all types of data, including healthcare, social media and transactional information. Together, these and other types of large and complex data sets have come to be known as Big Data. The influence of big data within the pharmaceutical industry is still emerging for organizations facing key medical, commercial, and HEOR decisions.

It is important for biopharmaceutical companies attempting to utilize Big Data in their decision-making to not only understand the most valuable data producers but also the most impactful way to disseminate Big Data analyses. This study presents benchmark data on these questions as well as who are the most frequent internal requestors of Big Data analysis and the presence of a Big Data team or function within benchmark participants. Best Practices, LLC utilized medical, commercial and HEOR segmented responses to investigate these issues. The study offers key benchmarks that will help leaders to better understand the growing influence of Big Data in the biopharmaceutical sector and how it impacts medical, HEOR and commercial operations in the U.S.

This study provides Medical, Commercial and HEOR segmented responses on survey questions.

KEY TOPICS

  • Executive Summary
  • Big Data Team Overview and Key Study Insights
  • Defining Big Data
  • Presence of Big Data Team
  • Data Producers, Dissemination, and Requestors

SAMPLE KEY METRICS
  • Centralized vs decentralized group supporting Big Data projects
  • Plans for dedicated Big Data teams
  • Impact / value of data producers
  • Impact of data dissemination channels
  • Target audiences for data analysis
  • Frequency of data requests by source

SAMPLE KEY FINDING
  • Majority of Each Segment Rate Internal Groups as Most Impactful Targets for Data Analysis: Internal Commercial, Medical and Development functions were rated by a majority of medical, commercial and HEOR respondents as the most impactful targets for data analysis presentations. A majority of each segment also said these internal groups were also the most frequent requestors of presentations.

METHODOLOGY

Best Practices, LLC engaged 22 leaders from 18 pharmaceutical companies through a benchmarking survey.áResearch analysts also conducted seven deep-dive executive interviews with selected benchmarká participants.

Industries Profiled:
Pharmaceutical; Health Care; Biotech; Chemical; Medical Device; Manufacturing; Consumer Products; Diagnostic; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Merck; Merck Serono; Novartis; Boehringer Ingelheim; Genentech; Teva Pharmaceutical Industries Ltd; Pfizer; Baxter Healthcare; GlaxoSmithKline ; Bayer; Gilead Sciences; Janssen; Lundbeck; Sanofi; Esteve; Daiichi Sankyo; Purdue Pharma; AstraZeneca


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.